Canaccord Genuity Initiates Coverage of Natera With Buy Rating

Jan 06, 2017

|

NEW YORK (GenomeWeb) – Canaccord Genuity today initiated coverage of molecular diagnostics company Natera with a Buy rating. It set a price target of $18.00 for the company's stock.

The San Carlos, California-based company markets a sequencing-based noninvasive prenatal test and is developing cancer products that analyze circulating tumor DNA.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.

Menu

Canaccord Genuity Initiates Coverage of Natera With Buy Rating

To read the full story....

Breaking News

CDC Reverses Position, Says Asymptomatic Patients Should Be Tested for SARS-CoV-2

Roche Nabs CE Mark for SARS-CoV-2 Quantitative Antibody Test

Foundation Medicine, Takeda Collaborate to Develop CDx for NSCLC Therapies

FDA Grants Emergency Use Authorization to Coronavirus Tests From Visby Medical, SNIBE

Mount Sinai Coronavirus Antibody Test Gets NYSDOH Emergency Use Authorization for Quantitative Use

In Brief This Week: Illumina, Siemens Healthineers, Danaher, Abbott, and More

Featured White Papers

Moving from Non-Invasive Prenatal Screening to Prenatal Diagnostics: An Expert Panel Discussion

Navigating the FDA's EUA Process for Diagnostics in the Present and Future: A Stakeholder Panel Discussion

What's Popular?

FDA Publishes First Batch of SARS-CoV-2 MDx Limit of Detection Comparison Results

FDA Grants Emergency Use Authorization to Coronavirus Tests From Visby Medical, SNIBE

CDC Reverses Position, Says Asymptomatic Patients Should Be Tested for SARS-CoV-2

Qiagen Acquires Remaining Stake in NeuMoDx Molecular for $248M

Roche Gets FDA Emergency Use Authorization for Rapid Coronavirus, Flu Test

Sponsorships